Identifying people at a high risk of developing pancreatic cancer

Nature Reviews Cancer

Volumn 13, Issue 1, 2013, Pages 66-74

  Klein, Alison P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA2 PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PROTEIN KINASE LKB1; PROTEIN MLH1; PROTEIN MSH2;

ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER SUSCEPTIBILITY; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE COURSE; ENDOSCOPIC ECHOGRAPHY; FAMILY HISTORY; FIRST DEGREE RELATIVE; FOLLOW UP; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; GENOTYPE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HEREDITY; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; OVARY CANCER; PANCREAS CANCER; PANCREAS RESECTION; PATIENT COUNSELING; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; STANDARDIZED INCIDENCE RATIO; STANDARDIZED MORTALITY RATIO;

CARCINOMA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; PANCREATIC NEOPLASMS; PEDIGREE; REGISTRIES; RISK ASSESSMENT;

EID: 84871715774     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3420     Document Type: Review

References (75)

1. Howlader, N. et al. SEER Cancer Statistics Review, 1975-2005. National Cancer Institute [online], http://seer.cancer.gov/csr/1975-2005/(2010).
2. Cleary, S. P. et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J. Am. Coll. Surg. 198, 722-731 (2004).
3. Klein, A. P. et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 64, 2634-2638 (2004).
4. Brune, K. A. et al. Importance of age of onset in pancreatic cancer kindreds. J. Natl Cancer Inst. 102, 119-126 (2010).
5. Goggins, M. et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 56, 5360-5364 (1996).
6. Jones, S. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217 (2009).
7. Roberts, N. J. et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2, 41-46 (2012).
8. Warthin, A. S. Heredity with reference to carcinoma. Arch. Intern. Med. 12, 546-555 (1913).
9. Douglas, J. A. et al. History and molecular genetics of Lynch syndrome in family G: a century later. JAMA 294, 2195-2202 (2005).
10. MacDermott, R. P. & Kramer, P. Adenocarcinoma of the pancreas in four siblings. Gastroenterology 65, 137-139 (1973).
11. Friedman, J. M. & Fialkow, P. J. Carcinoma of the pancreas in four brothers. Birth Defects Orig. Artic. Ser. 12, 145-150 (1976).
12. Reimer, R. R., Fraumeni, J. F. Jr, Ozols, R. F. & Bender, R. Pancreatic cancer in father and son. Lancet 1, 911 (1977).
13. Danes, B. S. & Lynch, H. T. A familial aggregation of pancreatic cancer. An in vitro study. JAMA 247, 2798-2802 (1982).
14. Dat, N. M. & Sontag, S. J. Pancreatic carcinoma in brothers. Ann.Intern.Med. 97, 282 (1982).
15. Katkhouda, N. & Mouiel, J. Pancreatic cancer in mother and daughter. Lancet 2, 747 (1986).
16. Ghadirian, P., Simard, A. & Baillargeon, J. Cancer of the pancreas in two brothers and one sister. Int. J. Pancreatol. 2, 383-391 (1987).
17. Klein, A. P., Hruban, R. H., Brune, K. A., Petersen, G. M. & Goggins, M. Familial pancreatic cancer. Cancer J. 7, 266-273 (2001).
18. Falk, R. T., Pickle, L. W., Fontham, E. T., Correa, P. & Fraumeni, J. F. Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am. J. Epidemiol. 128, 324-336 (1988).
19. Friedman, G. D. & Van Den Eeden, S. K. Risk factors for pancreatic cancer: an exploratory study. Int. J. Epidemiol. 22, 30-37 (1993).
20. Fernandez, E., La Vecchia, C., d'Avanzo, B., Negri, E. & Franceschi, S. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 3, 209-212 (1994).
21. Price, T. F., Payne, R. L. & Oberleitner, M. G. Familial pancreatic cancer in south Louisiana. Cancer Nurs. 19, 275-282 (1996).
22. Ghadirian, P. et al. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int. J. Pancreatol. 10, 183-196 (1991).
23. Coughlin, S. S., Calle, E. E., Patel, A. V. & Thun, M. J. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 11, 915-923 (2000).
24. Schenk, M. et al. Familial risk of pancreatic cancer. J. Natl Cancer Inst. 93, 640-644 (2001).
25. Silverman, D. T. Risk factors for pancreatic cancer: a case-control study based on direct interviews. Teratog. Carcinog. Mutagen. 21, 7-25 (2001).
26. Jacobs, E. J. et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int. J. Cancer 127, 1421-1428 (2010).
27. Goggins, M. et al. Use and benefits of a Web site for pancreatic cancer. JAMA 280, 1309-1310 (1998).
28. Petersen, G. M. & Hruban, R. H. Familial pancreatic cancer: where are we in 2003? J. Natl Cancer Inst. 95, 180-181 (2003).
29. Hruban, R. H., Petersen, G. M., Ha, P. K. & Kern, S. E. Genetics of pancreatic cancer. From genes to families. Surg. Oncol. Clin. N. Am. 7, 1-23 (1998).
30. Klein, A. P. et al. Evidence for a major gene influencing risk of pancreatic cancer. Genet. Epidemiol. 23, 133-149 (2002).
31. Bartsch, D. K. et al. Prevalence of familial pancreatic cancer in Germany. Int. J. Cancer 110, 902-906 (2004).
32. Schneider, R. et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam. Cancer 10, 323-330 (2011).
33. Greenhalf, W., Malats, N., Nilsson, M., Bartsch, D. & Neoptolemos, J. International registries of families at high risk of pancreatic cancer. Pancreatology 8, 558-565 (2008).
34. Petersen, G. et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol. Biomarkers Prev. 15, 704-710 (2006).
35. James, T. A. et al. Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer 101, 2722-2726 (2004).
36. Wang, L. et al. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 18, 2829-2834 (2009).
37. Murphy, K. M. et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 62, 3789-3793 (2002).
38. Hahn, S. A. et al. BRCA2 germline mutations in familial pancreatic carcinoma. J. Natl Cancer Inst. 95, 214-221 (2003).
39. Couch, F. J. et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 16, 342-346 (2007).
40. Thompson, D. & Easton, D. F. Cancer Incidence in BRCA1 mutation carriers. J. Natl Cancer Inst. 94, 1358-1365 (2002).
41. Ferrone, C. R. et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J. Clin. Oncol. 27, 433-438 (2009).
42. Axilbund, J. E. et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol. Ther. 8, 1-5 (2009).
43. Rutter, J. L. et al. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study. Cancer 101, 2809-2816 (2004).
44. Vasen, H. F. et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int. J. Cancer 87, 809-811 (2000).
45. Kastrinos, F. et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302, 1790-1795 (2009).
46. van Lier, M. G. et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am. J. Gastroenterol. 105, 1258-1264 (2010).
47. Lowenfels, A. B. et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J. Natl Cancer Inst. 89, 442-446 (1997).
48. Whitcomb, D. C. et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nature Genet. 14, 141-145 (1996).
49. Whitcomb, D. C. et al. A gene for hereditary pancreatitis maps to chromosome 7q35. Gastroenterology 110, 1975-1980 (1996).
50. Witt, H. et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nature Genet. 25, 213-216 (2000).
51. Lowenfels, A. B., Maisonneuve, P., Whitcomb, D. C., Lerch, M. M. & DiMagno, E. P. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 286, 169-170 (2001).
52. Iodice, S., Gandini, S., Maisonneuve, P. & Lowenfels, A. B. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch. Surg. 393, 535-545 (2008).
53. Chari, S. T. et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129, 504-511 (2005).
54. Arslan, A. A. et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch. Intern. Med. 170, 791-802 (2010).
55. Lucenteforte, E. et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann. Oncol. 23, 374-382 (2012).
56. Suarez, B. K. Hampe, G. L. & Van Eerdewegh, P. in Genetic Approaches to Mental Disorders (eds Gershon, E.S. & Cloning, C. R.) 23-46 (Amereican Psyscological Association, 1994).
57. Rahman, N. et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genet. 39, 165-167 (2007).
58. Tischkowitz, M. D. et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 137, 1183-1186 (2009).
59. Slater, E. P. et al. PALB2 mutations in European familial pancreatic cancer families. Clin. Genet. 78, 490-494 (2010).
60. Claus, E. B., Risch, N. J. & Thompson, W. D. Age at onset as an indicator of familial risk of breast cancer. Am. J. Epidemiol. 131, 961-972 (1990).
61. Gail, M. H. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81, 1879-1886 (1989).
62. Chen, S., Wang, W., Broman, K. W., Katki, H. A. & Parmigiani, G. BayesMendel: and R Environment for Mendelian Risk Prediction. Stat. Appl. Genet. Mol. Biol. 3, 21 (2004).
63. Wang, W. et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J. Clin. Oncol. 25, 1417-1422 (2007).
64. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
65. Gold, D. V. et al. PAM4 enzyme immunoassay alone and in combination with CA 19-19 for the detection of pancreatic adenocarcinoma. Cancer 16 Aug 2012 (doi:10.1002/cncr.27762).
66. Canto, M. I. et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142, 796-804 (2012).
67. Kelly, K. A. et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med. 5, e85 (2008).
68. Canto, M. I. et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin. Gastroenterol. Hepatol 2, 606-621 (2004).
69. Brentnall, T. A., Bronner, M. P., Byrd, D. R., Haggitt, R. C. & Kimmey, M. B. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann.Intern.Med. 131, 247-255 (1999).
70. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
71. McCabe, N. et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol. Ther. 4, 934-936 (2005).
72. van der Heijden, M. S. et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin. Cancer Res. 11, 7508-7515 (2005).
73. Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244 (2010).
74. Villarroel, M. C. et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol. Cancer Ther. 10, 3-8 (2010).
75. Howes, N. et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin. Gastroenterol. Hepatol. 2, 252-261 (2004).